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We welcome the recent BMJ Global Health 
Commentary noting the low African author-
ship of pandemic- related published research.1 
This finding follows a long- term relative 
dearth of African- led research and publica-
tion on global health matters, which in turn 
has weakened African leadership in setting 
global health research priorities and agendas. 
African researchers and manufacturers have 
long pointed2–5 to the dangers for local health 
security of extreme import dependence and 
reliance on very few international suppliers 
(‘concentration risk’), yet that argument has 
struggled to gain an international hearing.
However, the impact of COVID-19 in Africa 
has conclusively demonstrated the dangers of 
siloed health systems planning, funding and 
research that ignores the implications of local 
medical technologies manufacturing capabil-
ities for local health security and resilience. 
African health systems have been damaged 
during the pandemic by a toxic combination 
of high import dependence, low purchasing 
power allowing African countries to be outbid 
for resources and relatively low local manu-
facturing capabilities. The resultant supply 
chain crisis has shown the critical nature 
of local manufacturing for tackling local 
medical emergencies and generating local 
health security.
Collaborative evidence- sharing by African 
manufacturers and other stakeholders in a 
closed webinar in October 20206 documented 
how, as the pandemic hit African countries, 
externally sourced supplies of essential drugs 
and other commodities vanished. Local 
manufacturers saw input prices shoot up on 
global markets, inputs become unobtainable 
and freight charges escalate, as local health-
care institutions and governments desper-
ately turned to local industry for replacement 
supplies. The scaling up and innovation by 
some local manufacturers has been impressive, 
as has the speed and flexibility of industrial 
problem- solving by some research institutes 
and governments. Examples from several 
countries6 include: restarting and scaling 
up hand sanitiser production, using local 
ethanol and adapted plastic bottle delivery 
systems; making local swabs from scratch and 
scaling up viral transport medium output, 
alongside developing PCR test kits for local 
laboratories; making locally produced masks 
and protective equipment while struggling to 
replace meltblown fabric imports suddenly 
unavailable; scaling up dexamethasone 
production; and inventing and producing 
local ventilators and low- tech oxygen therapy 
delivery methods. A Southern African manu-
facturer noted that some innovations were by 
‘people who weren’t given the opportunity to 
innovate in a pre- Covid world’.6
African countries where local manufac-
turers responded more effectively than else-
where have generally possessed broader and 
deeper industrial structures. They could also 
Summary box
 ► African commentators have long emphasised the 
importance of local manufacturing for local health 
security, but the argument has struggled to gain an 
international hearing.
 ► COVID-19 has, however, demonstrated the health 
dangers from extreme import dependence and low 
purchasing power; it has also shown the scope and 
capability for local industrial innovation.
 ► Local innovation and manufacturing scale- up during 
the pandemic was facilitated by adaptable govern-
ment procurement policies and a health research 
base with strong links to manufacturing.
 ► Constraints included lack of local testing and ac-
creditation facilities, and skill and finance shortages.
 ► African researchers and planners should be heard 
and supported when focusing on localising supply 
chains and tackling severe concentration risk in the 
interests of local health security.
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turn to local universities as innovation centres to support 
adaptation and upgrading. Adaptable government 
procurement, and a health research base with strong links 
to manufacturing, have been national facilitators in some 
cases, while in some instances, a dearth of competent 
governance institutions has been a hurdle. Conversely, a 
lack of rapid and effective local testing and accreditation 
facilities, scarcity of key high level technical and regula-
tory skills, and lack of patient capital funding have been 
blockages on local innovation6 and agile responses to the 
pandemic.
Furthermore, these are not just lessons for African 
policy makers: active pharmaceutical ingredient (API), 
medical devices (including ventilators and personal 
protective equipment (PPE)) and medicines produc-
tion concentration risk is global. African countries have 
suffered severely from a globally transmitted supply chain 
crisis, through competitive procurement by governments 
with deeper pockets that drove price hikes, and national 
export controls on essential commodities and raw mate-
rials that blocked access. Globally, health systems and 
global health research has very rarely incorporated 
research questions or expertise on local industrial devel-
opment and their link to local health security as well as 
systemic agility and resilience during pandemics. Manu-
facturing supply chains and industrial development are 
very rarely included, as they should be, in the social 
determinants of health.5 When global health has turned 
its attention to supply chains, as in WHO prequalification 
initiatives or global fund purchasing rules, the result has 
often been to generate dependence on a few suppliers.4 
The pandemic has foregrounded longer standing worries 
about global, and specifically Indian, over- dependence 
on API supplies from China.7 8
To challenge the exclusionary and disequalising 
dynamic represented by the wave of ‘crisis nationalism’ 
in monopolising essential supplies, of which ‘vaccine 
nationalism’ has the highest profile,9 10 research and 
planning for health security must turn greater attention 
to localising supply chains and tackling severe concen-
tration risk. Addressing the severe deficit of health secu-
rity in most of Africa requires medium- term investment 
in broadening and deepening the local industrial base. 
This in turn means re- thinking the public health system’s 
role in stimulating local industrial development, through 
innovative procurement, assured markets for local manu-
facturers and shaping technological upgrading, while 
building on the pandemic- strengthened collaborative 
capabilities between multiple public and private stake-
holders in many countries.
The pandemic has taught once more that global 
health security is built on robust local health security 
foundations. It has also foregrounded the fragility of 
health- industrial supply chains in African (and other 
developing) countries and their reinforcing impact 
on global inequalities. The silos of health versus indus-
trial research now need definitive breaking down. It is 
time for global health research funders, planners and 
researchers to work much more closely with industrial 
and innovation experts, and to give space to, and rein-
force, crisis- generated African research, agency, expertise 
and leverage in shaping local industrial and technolog-
ical development for local and global health security—
ahead of the next pandemic. The local health–industrial 
complex as a coalition nucleus for building robust local 
health security and by extension resilient global health 
security has been ignored for too long.
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